BioSpace News Archive

The Foundation for Sarcoidosis Research is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2023-2025 is being awarded to Dr. Christen Vagts from FSR Global Sarcoidosis Clinic Alliance Founding Member, University of Illinois Hospital and Clinic, for her outstanding proposal, Immune Mediators of Active Advanced Pulmonary Sarcoidosis.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Company has received approval to conduct clinical trial of its second generation pan-TRK inhibitor zurletrectinib (ICP-723) to treat pediatric patients (2 to 12 years old) in China.

Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV) today announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs.

SQZ Biotechnologies Company (OTC: SQZB) (the “Company” or “SQZ”) today announced that Roche has determined that it will not exercise its option for HPV 16 positive solid tumors under the SQZ-APC-HPV program.

MoonLake Immunotherapeutics AG today announced that it has successfully completed randomization of the target 200 patients, several weeks ahead of schedule, in its global Phase 2 ARGO clinical trial evaluating Nanobody® sonelokimab in active psoriatic arthritis (PsA).

BioAtla, Inc. today announced that it plans to host a conference call and webcast on Tuesday, August 1, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended June 30, 2023 and provide business highlights.

electroCore, Inc. today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study, in the Journal of Affective Disorders.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced participation in the following August investor conferences.

Aquestive Therapeutics, Inc. today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO.

Mr. McEnany will Continue to Serve as Catalyst’s Non-Executive Chairman of the Board Following his Retirement Nationally Recognized Executive Recruitment Firm has been Retained to Initiate Search.